Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1126

1.

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.

Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, Colecchia M, Giannatempo P, Mortarini R, Bianchi M, Farè E, Monopoli F, Colombo R, Gallina A, Salonia A, Messina A, Ali SM, Madison R, Ross JS, Chung JH, Salvioni R, Mariani L, Montorsi F.

J Clin Oncol. 2018 Oct 20:JCO1801148. doi: 10.1200/JCO.18.01148. [Epub ahead of print]

PMID:
30343614
2.

Comparative Genomic Profiling of Refractory/Metastatic Penile and non-Penile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy.

Jacob JM, Ferry EK, Gay LM, Elvin JA, Vergilio J, Ramkissoon S, Severson E, Necchi A, Killian JK, Ali SM, Schrock AB, Liu NW, Chung J, Miller VA, Stephens PJ, Welsh A, Corona RJ, Ross JS, Bratslavsky G.

J Urol. 2018 Oct 3. pii: S0022-5347(18)43962-6. doi: 10.1016/j.juro.2018.09.056. [Epub ahead of print]

PMID:
30291913
3.

Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study.

Roginiel AC, Dhruva SS, Ross JS.

Medicine (Baltimore). 2018 Oct;97(40):e12715. doi: 10.1097/MD.0000000000012715.

4.

Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling.

Qin A, Johnson A, Ross JS, Miller VA, Ali SM, Schrock AB, Gadgeel S.

J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33126-5. doi: 10.1016/j.jtho.2018.09.014. [Epub ahead of print]

PMID:
30267839
5.

Clinical Trials-We Get What We Pay For.

Ross JS.

JAMA Intern Med. 2018 Sep 24. doi: 10.1001/jamainternmed.2018.3930. [Epub ahead of print] No abstract available.

PMID:
30264093
6.

Will research preprints improve healthcare for patients?

Krumholz HM, Ross JS, Otto CM.

BMJ. 2018 Sep 24;362:k3628. doi: 10.1136/bmj.k3628. No abstract available.

PMID:
30249719
7.

An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis.

Necchi A, Giannatempo P, Raggi D, Mariani L, Colecchia M, Farè E, Monopoli F, Calareso G, Ali SM, Ross JS, Chung JH, Salvioni R.

Eur Urol. 2018 Sep 19. pii: S0302-2838(18)30660-2. doi: 10.1016/j.eururo.2018.09.010. [Epub ahead of print] No abstract available.

PMID:
30243800
8.

Geriatric Assessment: An Office-Based Approach.

Tatum Iii PE, Talebreza S, Ross JS.

Am Fam Physician. 2018 Jun 15;97(12):776-784.

PMID:
30216018
9.

State-Level Population Estimates of Individuals Subject to and Not Meeting Proposed Medicaid Work Requirements.

Silvestri DM, Holland ML, Ross JS.

JAMA Intern Med. 2018 Sep 10. doi: 10.1001/jamainternmed.2018.4196. [Epub ahead of print] No abstract available.

PMID:
30208409
10.

Time resolved detection of two-plasmon decay using three-halves harmonic emission on the National Ignition Facility.

Goyon C, Datte PS, Buscho JG, Butler NJ, Hernandez JE, Hohenberger M, Lechleiter BL, Michel P, Ross JS, Bell PM, Moody JD.

Rev Sci Instrum. 2018 Aug;89(8):083504. doi: 10.1063/1.5038094.

PMID:
30184717
11.

Genomic Landscape of Adult and Pediatric BCR-ABL1-Like B-Lymphoblastic Leukemia Using Parallel DNA and RNA Sequencing.

Severson EA, Vergilio JA, Gay LM, Daniel S, Hemmerich AC, Elvin JA, Britt N, Nahas M, Cohen MB, Brown C, Sathyan P, Rankin A, Miller V, Ross JS, Ramkissoon SH.

Oncologist. 2018 Sep 4. pii: theoncologist.2018-0272. doi: 10.1634/theoncologist.2018-0272. [Epub ahead of print]

PMID:
30181314
12.

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

Fabrizio DA, George TJ Jr, Dunne RF, Frampton G, Sun J, Gowen K, Kennedy M, Greenbowe J, Schrock AB, Hezel AF, Ross JS, Stephens PJ, Ali SM, Miller VA, Fakih M, Klempner SJ.

J Gastrointest Oncol. 2018 Aug;9(4):610-617. doi: 10.21037/jgo.2018.05.06.

13.

Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies.

Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00235. Epub 2018 Jul 13.

14.
15.

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.

Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F.

Oncologist. 2018 Aug 14. pii: theoncologist.2018-0058. doi: 10.1634/theoncologist.2018-0058. [Epub ahead of print]

PMID:
30108156
16.

Real-World Evidence: Promise and Peril For Medical Product Evaluation.

Dhruva SS, Ross JS, Desai NR.

P T. 2018 Aug;43(8):464-472.

17.

Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.

Kaplan HG, Rostad S, Ross JS, Ali SM, Millis SZ.

J Natl Compr Canc Netw. 2018 Aug;16(8):967-974. doi: 10.6004/jnccn.2018.7033.

PMID:
30099373
18.

Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study.

Jeffery MM, Hooten WM, Henk HJ, Bellolio MF, Hess EP, Meara E, Ross JS, Shah ND.

BMJ. 2018 Aug 1;362:k2833. doi: 10.1136/bmj.k2833.

19.

Medicare Beneficiary Out-of-Pocket Costs for Generic Cardiovascular Medications Available Through $4 Generic Drug Discount Programs.

Liu P, Dhruva SS, Shah ND, Ross JS.

Ann Intern Med. 2018 Jul 24. doi: 10.7326/M18-0965. [Epub ahead of print] No abstract available.

PMID:
30039170
20.
21.

Off-label Use of Medications-Reply.

Wallach JD, Ross JS.

JAMA. 2018 Jul 17;320(3):307-308. doi: 10.1001/jama.2018.6521. No abstract available.

PMID:
30027247
22.

Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation.

Puthumana J, Wallach JD, Ross JS.

JAMA. 2018 Jul 17;320(3):301-303. doi: 10.1001/jama.2018.7619. No abstract available.

PMID:
30027239
23.

Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy.

Necchi A, Bratslavsky G, Corona RJ, Chung JH, Millis SZ, Elvin JA, Vergilio JA, Suh J, Ramkissoon S, Severson E, Daniel S, Killian JK, Ali SM, Schrock AB, Reddy P, Miller VA, Welsh A, Gay LM, Ross JS.

Eur Urol Focus. 2018 Jul 16. pii: S2405-4569(18)30179-2. doi: 10.1016/j.euf.2018.07.013. [Epub ahead of print]

PMID:
30025711
24.

Patterns and predictors of off-label prescription of psychiatric drugs.

Vijay A, Becker JE, Ross JS.

PLoS One. 2018 Jul 19;13(7):e0198363. doi: 10.1371/journal.pone.0198363. eCollection 2018.

25.

Early Experiences With Journal Data Sharing Policies: A Survey of Published Clinical Trial Investigators.

Tannenbaum S, Ross JS, Krumholz HM, Desai NR, Ritchie JD, Lehman R, Gamble GM, Bachand J, Schroter S, Groves T, Gross CP.

Ann Intern Med. 2018 Oct 16;169(8):586-588. doi: 10.7326/M18-0723. Epub 2018 Jul 17. No abstract available.

PMID:
30014127
26.

Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors.

O'Connor JM, Seidl-Rathkopf K, Torres AZ, You P, Carson KR, Ross JS, Gross CP.

Oncologist. 2018 Jul 16. pii: theoncologist.2017-0673. doi: 10.1634/theoncologist.2017-0673. [Epub ahead of print]

PMID:
30012876
27.

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.

Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN Jr, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB.

J Thorac Oncol. 2018 Oct;13(10):1560-1568. doi: 10.1016/j.jtho.2018.06.019. Epub 2018 Jul 5.

PMID:
29981927
28.

Fusion Energy Output Greater than the Kinetic Energy of an Imploding Shell at the National Ignition Facility.

Le Pape S, Berzak Hopkins LF, Divol L, Pak A, Dewald EL, Bhandarkar S, Bennedetti LR, Bunn T, Biener J, Crippen J, Casey D, Edgell D, Fittinghoff DN, Gatu-Johnson M, Goyon C, Haan S, Hatarik R, Havre M, Ho DD, Izumi N, Jaquez J, Khan SF, Kyrala GA, Ma T, Mackinnon AJ, MacPhee AG, MacGowan BJ, Meezan NB, Milovich J, Millot M, Michel P, Nagel SR, Nikroo A, Patel P, Ralph J, Ross JS, Rice NG, Strozzi D, Stadermann M, Volegov P, Yeamans C, Weber C, Wild C, Callahan D, Hurricane OA.

Phys Rev Lett. 2018 Jun 15;120(24):245003. doi: 10.1103/PhysRevLett.120.245003.

PMID:
29956968
29.

The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data.

Wilcox MA, Savitz AJ, Addington AM, Gray GS, Guinan EC, Jackson JW, Lehner T, Normand SL, Ranu H, Senthil G, Spertus J, Valeri L, Ross JS.

NPJ Schizophr. 2018 Jun 27;4(1):14. doi: 10.1038/s41537-018-0055-7. Review.

30.

Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA.

Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, Fendler B, Young L, Zhao M, Coyne M, Breese V, Young G, Donahue A, Pavlick D, Tsiros A, Brennan T, Zhong S, Mughal T, Bailey M, He J, Roels S, Frampton GM, Spoerke JM, Gendreau S, Lackner M, Schleifman E, Peters E, Ross JS, Ali SM, Miller VA, Gregg JP, Stephens PJ, Welsh A, Otto GA, Lipson D.

J Mol Diagn. 2018 Sep;20(5):686-702. doi: 10.1016/j.jmoldx.2018.05.004. Epub 2018 Jun 22.

31.

Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas.

Ramkissoon LA, Britt N, Guevara A, Whitt E, Severson E, Sathyan P, Gay L, Elvin J, Ross JS, Brown C, Stogner-Underwood K, Mott R, Kram D, Strowd R, Lesser GJ, Ramkissoon SH.

Curr Treat Options Oncol. 2018 Jun 21;19(8):41. doi: 10.1007/s11864-018-0559-4. Review.

PMID:
29931654
32.

Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis.

Mangray S, Kelly DR, LeGuellec S, Fridman E, Aggarwal S, Shago M, Matoso A, Madison R, Pramanik S, Zhong S, Li R, Lombardo KA, Cramer S, Pressey J, Ross JS, Corona RJ, Bratslavsky G, Argani P, Coindre JM, Somers GR, Ali SM, Yakirevich E.

Am J Surg Pathol. 2018 Oct;42(10):1360-1369. doi: 10.1097/PAS.0000000000001098.

PMID:
29901569
33.

Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling.

Tarlock K, Zhong S, He Y, Ries R, Severson E, Bailey M, Morley S, Balasubramanian S, Erlich R, Lipson D, Otto GA, Vergillo JA, Kolb EA, Ross JS, Mughal T, Stephens PJ, Miller V, Meshinchi S, He J.

Oncotarget. 2018 May 29;9(41):26417-26430. doi: 10.18632/oncotarget.25443. eCollection 2018 May 29.

34.

Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators.

Bates J, Parzynski CS, Dhruva SS, Coppi A, Kuntz R, Li SX, Marinac-Dabic D, Masoudi FA, Shaw RE, Warner F, Krumholz HM, Ross JS.

Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):848-856. doi: 10.1002/pds.4565. Epub 2018 Jun 12.

PMID:
29896873
35.

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.

Schrock AB, Zhu VW, Hsieh WS, Madison R, Creelan B, Silberberg J, Costin D, Bharne A, Bonta I, Bosemani T, Nikolinakos P, Ross JS, Miller VA, Ali SM, Klempner SJ, Ou SI.

J Thorac Oncol. 2018 Sep;13(9):1312-1323. doi: 10.1016/j.jtho.2018.05.027. Epub 2018 Jun 5.

36.

The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.

Wallach JD, Ross JS, Naci H.

Clin Trials. 2018 Jun;15(3):219-229. doi: 10.1177/1740774518770648.

PMID:
29871509
37.

The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation.

Wallach JD, Ross JS, Naci H.

Clin Trials. 2018 Jun;15(3):243-246. doi: 10.1177/1740774518770657. No abstract available.

PMID:
29871507
38.

Fulfilling the Promise of Unique Device Identifiers.

Dhruva SS, Ross JS, Schulz WL, Krumholz HM.

Ann Intern Med. 2018 Aug 7;169(3):183-185. doi: 10.7326/M18-0526. Epub 2018 Jun 5. No abstract available.

PMID:
29868760
39.

Network Optimization And The Continuity Of Physicians In Medicaid Managed Care.

Ndumele CD, Staiger B, Ross JS, Schlesinger MJ.

Health Aff (Millwood). 2018 Jun;37(6):929-935. doi: 10.1377/hlthaff.2017.1410.

PMID:
29863934
40.

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.

O'Connor JM, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP.

JAMA Oncol. 2018 Aug 1;4(8):e180798. doi: 10.1001/jamaoncol.2018.0798. Epub 2018 Aug 9.

PMID:
29800974
41.

Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.

Wallach JD, Egilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, Schwartz LM, Ross JS.

BMJ. 2018 May 24;361:k2031. doi: 10.1136/bmj.k2031.

42.

Review of clinical trial settings of drugs commonly used in primary care and approved between 2005 and 2012.

Crossley JR, Tan TP, Smith KH, Ross JS, Merenstein DJ.

J Gen Intern Med. 2018 Sep;33(9):1431-1432. doi: 10.1007/s11606-018-4486-7. No abstract available.

PMID:
29777429
43.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

PMID:
29773717
44.

Publication and Dissemination of Results in Clinical Trials of Neurology.

Sreekrishnan A, Mampre D, Ormseth C, Miyares L, Leasure A, Ross JS, Sheth KN.

JAMA Neurol. 2018 Jul 1;75(7):890-891. doi: 10.1001/jamaneurol.2018.0674. No abstract available.

PMID:
29710083
45.

The Impact of Off-Patent Drug Acquisitions on Prices.

Gupta R, Henkel A, Forman HP, Ross JS.

J Gen Intern Med. 2018 Jul;33(7):1007-1009. doi: 10.1007/s11606-018-4372-3. No abstract available.

PMID:
29687433
46.

Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens.

Severson EA, Riedlinger GM, Connelly CF, Vergilio JA, Goldfinger M, Ramkissoon S, Frampton GM, Ross JS, Fratella-Calabrese A, Gay L, Ali S, Miller V, Elvin J, Hadigol M, Hirshfield KM, Rodriguez-Rodriguez L, Ganesan S, Khiabanian H.

Blood. 2018 May 31;131(22):2501-2505. doi: 10.1182/blood-2018-03-840629. Epub 2018 Apr 20. No abstract available.

PMID:
29678827
47.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, Choueiri TK.

Br J Cancer. 2018 May;118(9):1238-1242. doi: 10.1038/s41416-018-0064-3. Epub 2018 Apr 20.

PMID:
29674707
48.

Older drugs with infantile evidence: the illustrative example of loop diuretics.

Bikdeli B, Testani JM, Ross JS, Krumholz HM.

Eur Heart J Qual Care Clin Outcomes. 2018 Jul 1;4(3):232-234. doi: 10.1093/ehjqcco/qcy012. No abstract available.

PMID:
29617967
49.

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.

Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW.

Clin Cancer Res. 2018 Jul 1;24(13):3059-3068. doi: 10.1158/1078-0432.CCR-18-0373. Epub 2018 Apr 3.

PMID:
29615459
50.

National Prescribing Trends for High-Risk Anticholinergic Medications in Older Adults.

Rhee TG, Choi YC, Ouellet GM, Ross JS.

J Am Geriatr Soc. 2018 Jul;66(7):1382-1387. doi: 10.1111/jgs.15357. Epub 2018 Mar 26.

PMID:
29582410

Supplemental Content

Support Center